Lowest Price Guaranteed From USD 5,499
Published
November 2020
Pages
426
View Count
4148
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Since the success of ADCETRIS® (approved in 2011), antibody drug conjugates (ADCs) are now considered a versatile therapeutic tool and have been accepted into the contemporary portfolio of mainstream healthcare solutions. Over time, clinical researchers have been able to further their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. Some of the recently approved ADC therapeutics include BLENREP® (2020), TRODELVYTM (2020), PadcevTM (2019) and POLIVY® (2019). In addition, there are close to 250 unique ADC product candidates under development. Several big pharma players, including AstraZeneca, GlaxoSmithKline, Pfizer, Roche and Takeda, have also acquired stake in this market. Moreover, the fact that companies involved in the development of ADCs, have received over USD 5 billion in capital investments (since 2011), attests to the therapeutic potential and growing popularity of this novel class of targeted therapeutics. However, the impending growth of the ADC therapeutics market highlights the rising importance of establishing advanced manufacturing capacities in order to meet the anticipated demand. Not all stakeholders in the industry possess end to end capabilities / infrastructure to support the design, development and manufacturing of these complex and highly potent pharmacological entities.
Owing to the fact that ADCs are highly potent, cytotoxic molecules, the manufacturing of such conjugated entities requires elaborate technical capabilities, along with manufacturing acumen related to both biologics and highly potent chemical substances. Specifically, the development of an antibody requires experience in protein engineering, cell line development, bioprocess development and related scale-up techniques. The production of the cytotoxic payloads, which are used in ADCs, requires contained manufacturing facilities, special equipment, and expertise in advanced chemical synthesis and purification techniques. In addition, the process is incomplete without state-of-art linker technologies, which are required for the final bioconjugation step, wherein the antibody component is attached to the cytotoxic payload. Given the aforementioned requirements, industry stakeholders generally do not (entirely) manufacture ADCs in-house. Presently, it is estimated that, 70-80% of ADC manufacturing operations are outsourced. This trend is likely to persist in the coming years, as well. In fact, even some of the leading players in this domain claim to be dependent on contract manufacturers for the supply of one or more components of their respective ADC products / product candidates. All these factors contribute towards increasing the complexity of ADC supply chain. However, as per the recent industry trends, the number of collaborations, strategic alliances and acquisitions have enabled the companies to offer integrated supply chain solutions. Given the anticipated growth in demand for ADCs, the contract manufacturing market in this domain is anticipated to witness substantial growth in the coming years.
The “ADC Contract Manufacturing Market (4th Edition) by Phase of Development (Commercial, Phase III, Phase II and Phase I), Type of Component Manufacturing (Antibody Manufacturing, HPAPI / Cytotoxic Payload and Linker Manufacturing, Conjugation and Fill / Finish), Target Indications (Solid Tumors, Hematological Malignancies and Others), Type of Payload Used (Maytansinoid, Auristatin, Pseudomonas Exotoxin, PBD and Others), Type of Linker Used (SMCC, VC, Hydrazone Linker, Peptide Linker, SPDB, and Others), Type of Antibody Origin (Humainzed, Human, Murine and Chimeric), Type of Antibody Isotype (IgG1, IgG2 and IgG4) and Geography (North America (the US, Canada, Mexico and Rest of North America), Europe (the UK, Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (Japan, China, Korea, Australia, India, Taiwan and Rest of Asia-Pacific), MENA (Israel, Saudi Arabia, UAE, Egypt), Latin America (Brazil, Peru, Argentina and Rest of Latin America) and Rest of the World), 2020-2030” report offers a comprehensive study of the current scenario and future potential of the ADC contract manufacturing market. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of this report was to evaluate the current opportunity and the future potential of the ADC contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] phase of development (commercial, phase III, phase II and phase I), [B] type of component manufacturing (antibody manufacturing, HPAPI / cytotoxic payload and linker manufacturing, conjugation and fill / finish), [C] target indications (solid tumors, hematological malignancies and others), [D] type of payload used (maytansinoid, auristatin, pseudomonas exotoxin, PBD and others), [E] type of linker used (SMCC, VC, hydrazone linker, peptide linker, SPDB, and others), [F] type of antibody origin (humainzed, human, murine and chimeric), [G] type of antibody isotype (IgG1, IgG2 and IgG4) and [H] geography (North America (US, Canada, Mexico and rest of North America), Europe (UK, Germany, France, Spain, Italy and rest of Europe), Asia-Pacific (Japan, China, Korea, Australia, India, Taiwan and rest of Asia-Pacific), MENA (Israel, Saudi Arabia, UAE, Egypt), Latin America (Brazil, Peru, Argentina and rest of Latin America) and rest of the world). To account for the uncertainties associated with the contract manufacturing of ADCs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report were also influenced by discussions held with key stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high level view on the likely evolution of the ADC contract manufacturing market in the mid to long term.
Chapter 3 is a general introduction to ADCs and the manufacturing requirements of such therapeutic products. It includes a detailed discussion on the structure of an ADC and its various components, manufacturing steps and associated challenges. The chapter also provides an overview of the growing trend of contract manufacturing, along with the challenges associated with supply chain and the growing demand for one-stop-shops. Further, it features a discussion on the various parameters that a sponsor company needs to consider while selecting a contract manufacturing partner.
Chapter 4 provides a comprehensive overview of contract manufacturers that are actively involved in the production or conjugation of ADCs. The chapter features information on company size, year of establishment, types of services offered (antibody manufacturing / HPAPI or cytotoxic payload manufacturing / linker manufacturing / conjugation / fill-finish), location of headquarters, location of manufacturing facilities, scale of operations (preclinical, clinical and commercial), and additional development services (proof-of-concept studies / process development and scale-up / anaytical development). The chapter also includes a list of various contract manufacturers offering antibody production services along with the information on the location of their headquarters. Further, it provides a list of HPAPI / cytotoxic payload contract manufacturers along with the information on location of facilities dedicated to the manufacturing of such components.
Chapter 5 features profiles of contract manufacturers that offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.
Chapter 6 features a detailed comparative analysis of the ADC contract manufacturers. The companies were compared on the basis of various parameters including supplier strength (company size and its experience in this field), service strength (number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities) and manufacturing strength (scale of operation and number of ADC manufacturing facilities).
Chapter 7 highlights the investments made by CMOs to expand or set up new facilities in order to support their ongoing operations. For each such instance, we have provided information on year of expansion, type of expansion (capacity expansion and new facility), type of service offered (manufacturing services, analytical / development services and fill / finish), geographical location of facility, scale of operation (preclinical, clinical and commercial) and most active players (in terms of number of instances).
Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked between different players in this market since 2012. It includes a brief description of the purpose of the partnership models (including research agreements, manufacturing agreements, technology licensing agreements, product development agreements and acquisitions / mergers). Further, it comprises of analysis based on year of agreement, type of agreement, key players and the geographical distribution of this activity.
Chapter 9 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing to a contract service provider.
Chapter 10 presents a value chain analysis featuring a detailed discussion on the various steps of the ADC manufacturing process, namely antibody manufacturing, payload, linker manufacturing, conjugation and fill / finish and the cost requirements across each of the aforementioned stages.
Chapter 11 features a comprehensive analysis of the overall installed manufacturing / bioconjugation capacity of contract manufacturers and an estimate of the quantity of ADCs that can be produced per batch. The analysis highlights the distribution of global capacity by company size (small-sized, mid-sized and large), geographical location of headquarters, geographical location of ADC manufacturing facilities and key players (in terms of highest bioconjugation capacity).
Chapter 12 provides a comprehensive overview of the market landscape of ADCs that are already approved and those that are under development (clinical and preclinical). This chapter includes information related to their current phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target indication(s), target antigen, antibody origin, antibody isotype, type of payload / warhead, type of linker and key players (in terms of number of preclinical molecules).
Chapter 13 features an elaborate discussion and competitive analysis of the various ADC conjugation approaches. This chapter also features an overview of the evolution of these technologies, highlighting the competition between contemporary technology platforms.
Chapter 14 features a comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). The analysis provides details related to the types of antibody isotopes, payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, trial phase, trial status, target indication, type of sponsor / collaborator, number of patients enrolled and duration of the trials.
Chapter 15 features a comprehensive analysis of the annual demand of ADCs (in grams) taking into account commercial, as well as clinical scale requirements. This was based on the parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
Chapter 16 presents a detailed regional capability assessment framework which compares the key geographies, based on a number of parameters, such as the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC capacity, number of registered clinical trials and demand for ADC’s in that particular geographical region.
Chapter 17 presents a comprehensive market forecast analysis, highlighting the likely growth of the contract manufacturing market of ADCs, till 2030. The chapter provides likely distribution of the projected future opportunity based on phase of development (commercial, phase III, phase II and phase I), type of component manufacturing (antibody manufacturing, HPAPI / cytotoxic payload and linker manufacturing, conjugation and fill / finish), target indications (solid tumors, hematological malignancies and others), type of payload used (maytansinoid, auristatin, pseudomonas exotoxin, PBD and others), type of linker used (SMCC, VC, hydrazone linker, peptide linker, SPDB, and others), type of antibody origin (humainzed, human, murine and chimeric), type of antibody isotype (IgG1, IgG2 and IgG4) and geography (North America (US, Canada, Mexico and rest of North America), Europe (UK, Germany, France, Spain, Italy and rest of Europe), Asia-Pacific (Japan, China, Korea, Australia, India, Taiwan and rest of Asia-Pacific), MENA (Israel, Saudi Arabia, UAE, Egypt), Latin America (Brazil, Peru, Argentina and rest of Latin America) and rest of the world(Malia and Chad)).
Chapter 18 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of ADC contract manufacturing market, under a comprehensive SWOT framework.
Chapter 19 highlights the effect of coronavirus outbreak on the ADC contract manufacturing market. It includes a brief discussion on the short-term and long-term impact of COVID-19 on the supply chain and market opportunity for drug developers and contract manufacturers. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future.
Chapter 20 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 21 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciar ini (Technical Business Development Manager, BSP Pharmaceuticals), Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics), John Burt (Chief Executive Officer, Abzena), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics), Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (Director of CDMO, Pierre Fabre), David Cunningham (Director Corporate Development, Goodwin Biotechnology), Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Piramal Pharma Solutions), Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services), Anonymous (Director, Business Development, Leading CMO) and Anonymous (Chief Executive Officer, Leading CMO).
Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 23 is an appendix, which provides the list of companies and organizations mentioned in the report.
Table Of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4 Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Components of Antibody Drug Conjugates (ADCs)
3.2.1. Antibody
3.2.2. Cytotoxin
3.2.3. Linker
3.3. ADC Manufacturing
3.3.1. Key Steps
3.3.2. Technical Challenges
3.3.3. Need for Outsourcing
3.4. Challenges Associated with Supply Chain and Method Transfer
3.4.1. Growing Demand for One-Stop-Shops and Integrated Service Providers
3.5. Selecting a CMO Partner
4. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturing Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Service(s) Offered
4.2.4. Analysis by Other ADC Services Offered
4.2.5. Analysis by Scale of Operation
4.2.6. Analysis by Location of Headquarters
4.2.7. Analysis by Location of Manufacturing Facility
4.3. List of Antibody Contract Manufacturing Service Providers
4.4. List of HPAPI / Cytotoxic Drug Contract Manufacturing Service Providers
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AbbVie Contract Manufacturing
5.2.1. Company Overview and Financial Information
5.2.2. ADC Offerings
5.2.3. Manufacturing Facilities
5.2.4. Recent Developments
5.2.5. Future Outlook
5.3. ADC Biotechnology
5.3.1. Company Overview and Financial Information
5.3.2. ADC Offerings
5.3.3. Manufacturing Facilities
5.3.4. Recent Developments
5.3.5. Future Outlook
5.4. Ajinomoto Bio-Pharma Services
5.4.1. Company Overview and Financial Information
5.4.2. ADC Offerings
5.4.3. Manufacturing Facilities
5.4.4. Recent Developments
5.4.5. Future Outlook
5.5. BOC Sciences
5.5.1. Company Overview and Financial Information
5.5.2. ADC Offerings
5.5.3. Manufacturing Facilities
5.5.4. Recent Developments
5.5.5. Future Outlook
5.6. BSP Pharmaceuticals
5.6.1. Company Overview
5.6.2. ADC Offerings
5.6.3. Manufacturing Facilities
5.6.5. Future Outlook
5.7. CARBOGEN AMCIS
5.7.1. Company Overview
5.7.2. ADC Offerings
5.7.3. Manufacturing Facilities
5.7.4. Recent Developments
5.7.5. Future Outlook
5.8. Cerbios-Pharma
5.8.1. Company Overview
5.8.2. ADC Offerings
5.8.3. Manufacturing Facilities
5.8.4. Recent Developments
5.8.5. Future Outlook
5.9. Creative Biolabs
5.9.1. Company Overview
5.9.2. ADC Offerings
5.9.3. Manufacturing Facilities
5.9.4. Recent Developments
5.9.5. Future Outlook
5.10. Goodwin Biotechnology
5.10.1. Company Overview
5.10.2. ADC Offerings
5.10.3. Manufacturing Facilities
5.10.4. Recent Developments
5.10.5. Future Outlook
5.11. Lonza
5.11.1. Company Overview and Financial Information
5.11.2. ADC Offerings
5.11.3. Manufacturing Facilities
5.11.4. Recent Developments
5.11.5. Future Outlook
5.12. MabPlex
5.12.1. Company Overview
5.12.2. ADC Offerings
5.12.3. Manufacturing Facilities
5.12.4. Recent Developments
5.12.5. Future Outlook
5.13. Millipore Sigma
5.13.1. Company Overview
5.13.2. ADC Offerings
5.13.3. Manufacturing Facilities
5.13.4. Recent Developments
5.13.5. Future Outlook
5.14. Novasep
5.14.1. Company Overview
5.14.2. ADC Offerings
5.14.3. Manufacturing Facilities
5.14.4. Future Outlook
5.15. Pierre Fabre
5.15.1. Company Overview and Financial Information
5.15.2. ADC Offerings
5.15.3. Manufacturing Facilities
5.15.4. Recent Developments
5.15.5. Future Outlook
5.16. Piramal Pharma Solutions
5.16.1. Company Overview and Financial Information
5.16.2. ADC Offerings
5.16.3. Manufacturing Facilities
5.16.4. Recent Developments
5.16.5. Future Outlook
5.17. WuXi Biologics
5.17.1. Company Overview and Financial Information
5.17.2. ADC Offerings
5.17.3. Manufacturing Facilities
5.17.4. Recent Developments
5.17.5. Future Outlook
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. ADC Contract Manufacturing Service Providers
6.3.1. ADC Contract Manufacturing Service Providers based in North America
6.3.2. ADC Contract Manufacturing Service Providers based in Europe
6.3.3. ADC Contract Manufacturing Service Providers based in Asia-Pacific and Rest of the World
7. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: RECENT EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturing Service Providers: Recent Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Type of Service(s) Offered
7.2.4. Analysis by Location of Expanded Facility
7.2.5. Analysis by Scale of Operation
7.2.6. Most Active Players: Analysis by Number of Expansions
8. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturing Service Providers: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Most Active Players: Analysis by Number of Partnerships
8.3.4. Regional Analysis
8.3.4.1. Most Active Players
8.3.4.2. Intercontinental and Intracontinental Agreements
9. MAKE VERSUS BUY DECISION MAKING
9.1. Chapter Overview
9.2. Assumptions and Parameter Definitions
9.2.1. Scenario 1
9.2.2. Scenario 2
9.2.3. Scenario 3
9.2.4. Scenario 4
9.3. Concluding Remarks
10. VALUE CHAIN ANALYSIS
10.1. Chapter Overview
10.2. ADC Development Value Chain
10.3. Cost Distribution Across the Value Chain
10.3.1. Cost Associated with Antibody Manufacturing
10.3.2. Cost Associated with Payload and Linker Manufacturing
10.3.3. Cost Associated with Conjugation
10.3.4. Cost Associated with Fill / Finish
11. ADC MANUFACTURING: CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. ADC Manufacturing: Global Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of Headquarters
11.3.3. Analysis by Location of Manufacturing Facilities
11.3.3.1 By Country
11.3.3.2. By Continent
11.3.4. Analysis by Key Players
12. ADC THERAPEUTICS: MARKET OVERVIEW
12.1. Chapter Overview
12.2. ADC Therapeutics: Clinical Pipeline
12.2.1. Analysis by Phase of Development
12.2.2. Analysis by Target Indication
12.2.3. Analysis by Target Antigen
12.2.4. Analysis by Antibody Origin
12.2.5. Analysis by Type of Antibody Isotype
12.2.6. Analysis by Payload Type
12.2.7. Analysis by Linker Type
12.3. ADC Therapeutics: Preclinical / Discovery Pipeline
12.3.1. Key Technology Providers: Analysis by Number of ADC Therapeutics
13. NOVEL ADC CONJUGATION TECHNOLOGY PLATFORMS
13.1. Chapter Overview
13.2. First Generation ADC Technologies
13.3. Second Generation ADC Technologies
13.3.1. Cysteine and Selenocysteine Engineering
13.3.2. Unnatural Amino Acid Engineering
13.3.3. Amino-Terminal Serine Engineering
13.4. Third Generation ADC Technologies
13.4.1. Enzyme-Assisted Ligation Approaches
13.4.2. Glycan Remodeling Approaches
13.4.3. Ligation at Fab Nucleotide-Binding Site
13.4.4. Cysteine Re-bridging
13.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
13.5. Evolutionary Analysis
14. GEOGRAPHICAL CLINICAL TRIALS ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. ADC Therapeutics: Overall Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis by Trial Phase
14.3.3. Analysis by Trial Status
14.3.4. Analysis by Type of Sponsor / Collaborator
14.3.5. Analysis by Type of Cancer
14.3.6. Most Active Players: Analysis by Number of Clinical Trials
14.3.7. Geographical Analysis by Number of Clinical Trials
14.3.8. Geographical Analysis by Enrolled Patient Population
14.4. ADC Therapeutics: Geographical Clinical Trial Analysis by Antibody Isotope
14.4.1. IgG1 based Molecules
14.4.1.1. Geographical Analysis by Trial Phase
14.4.1.2. Geographical Analysis by Trial Status
14.4.1.3. Geographical Analysis by Enrolled Patient Population
14.4.1.4. Analysis by Duration of Clinical Trials
14.4.2. IgG2 based Molecules
14.4.2.1. Geographical Analysis by Trial Phase
14.4.2.2. Geographical Analysis by Trial Status
14.4.2.3. Geographical Analysis by Enrolled Patient Population
14.4.2.4. Analysis by Duration of Clinical Trials
14.4.3. IgG4 based Molecules
14.4.3.1. Geographical Analysis by Trial Phase
14.4.3.2. Geographical Analysis by Trial Status
14.4.3.3. Geographical Analysis by Enrolled Patient Population
14.4.3.4. Analysis by Duration of Clinical Trials
14.5. ADC Therapeutics: Geographical Clinical Trial Analysis by Payload Type
14.5.1. Auristatin based Molecules
14.5.1.1. Geographical Analysis by Trial Phase
14.5.1.2. Geographical Analysis by Trial Status
14.5.1.3. Geographical Analysis by Enrolled Patient Population
14.5.1.4. Analysis by Duration of Clinical Trials
14.5.2. Maytansinoid based Molecules
14.5.2.1. Geographical Analysis by Trial Phase
14.5.2.2. Geographical Analysis by Trial Status
14.5.2.3. Geographical Analysis by Enrolled Patient Population
14.5.2.4. Analysis by Duration of Clinical Trials
14.5.3. Calicheamicin based Molecules
14.5.3.1. Geographical Analysis by Trial Phase
14.5.3.2. Geographical Analysis by Trial Status
14.5.3.3. Geographical Analysis by Enrolled Patient Population
14.5.3.4. Analysis by Duration of Clinical Trials
14.5.4. PBD based Molecules
14.5.4.1. Geographical Analysis by Trial Phase
14.5.4.2. Geographical Analysis by Trial Status
14.5.4.3. Geographical Analysis by Enrolled Patient Population
14.5.4.4. Analysis by Duration of Clinical Trials
14.5.5. Camptothecin based Molecules
14.5.5.1. Geographical Analysis by Trial Phase
14.5.5.2. Geographical Analysis by Trial Status
14.5.5.3. Geographical Analysis by Enrolled Patient Population
14.5.5.4. Analysis by Duration of Clinical Trials
14.5.6. Pyranoindolizinoquinoline based Molecules
14.5.6.1. Geographical Analysis by Trial Phase
14.5.6.2. Geographical Analysis by Trial Status
14.5.6.3. Geographical Analysis by Enrolled Patient Population
14.5.6.4. Analysis by Duration of Clinical Trials
14.5.7. Other Payload based Molecules
14.5.7.1. Geographical Analysis by Trial Phase
14.5.7.2. Geographical Analysis by Trial Status
14.5.7.3. Geographical Analysis by Enrolled Patient Population
14.5.7.4. Analysis by Duration of Clinical Trials
14.6. ADC Therapeutics: Geographical Clinical Trial Analysis by Linker Type
14.6.1. VC based Molecules
14.6.1.1. Geographical Analysis by Trial Phase
14.6.1.2. Geographical Analysis by Trial Status
14.6.1.3. Geographical Analysis by Enrolled Patient Population
14.6.1.4. Analysis by Duration of Clinical Trials
14.6.2. Hydrazone Linker based Molecules
14.6.2.1. Geographical Analysis by Trial Phase
14.6.2.2. Geographical Analysis by Trial Status
14.6.2.3. Geographical Analysis by Enrolled Patient Population
14.6.2.4. Analysis by Duration of Clinical Trials
14.6.3. SMCC based Molecules
14.6.3.1. Geographical Analysis by Trial Phase
14.6.3.2. Geographical Analysis by Trial Status
14.6.3.3. Geographical Analysis by Enrolled Patient Population
14.6.3.4. Analysis by Duration of Clinical Trials
14.6.4. Peptide Linker based Molecules
14.6.4.1. Geographical Analysis by Trial Phase
14.6.4.2. Geographical Analysis by Trial Status
14.6.4.3. Geographical Analysis by Enrolled Patient Population
14.6.4.4. Analysis by Duration of Clinical Trials
14.6.5. SPDB based Molecules
14.6.5.1. Geographical Analysis by Trial Phase
14.6.5.2. Geographical Analysis by Trial Status
14.6.5.3. Geographical Analysis by Enrolled Patient Population
14.6.5.4. Analysis by Duration of Clinical Trials
14.6.6. MC based Molecules
14.6.6.1. Geographical Analysis by Trial Phase
14.6.6.2. Geographical Analysis by Trial Status
14.6.6.3. Geographical Analysis by Enrolled Patient Population
14.6.6.4. Analysis by Duration of Clinical Trials
14.6.7. Others Type Linker based Molecules
14.6.7.1. Geographical Analysis by Trial Phase
14.6.7.2. Geographical Analysis by Trial Status
14.6.7.3. Geographical Analysis by Enrolled Patient Population
14.6.7.4. Analysis by Duration of Clinical Trials
15. ADC THERAPEUTICS: DEMAND ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. ADC Therapeutics: Overall Annual Demand
15.3.1. ADC Therapeutics: Annual Commercial Demand
15.3.1.1. Analysis by Type of Cancer
15.3.1.2. Analysis by Antibody Origin
15.3.1.3. Analysis by Type of Antibody Isotype
15.3.1.4. Analysis by Payload Type
15.3.1.5. Analysis by Linker Type
15.3.2. ADC Therapeutics: Annual Clinical Demand
15.3.2.1. Analysis by Phase of Development
15.3.2.2. Analysis by Type of Cancer
15.3.2.3. Analysis by Antibody Origin
15.3.2.4. Analysis by Type of Antibody Isotype
15.3.2.5. Analysis by Payload Type
15.3.2.6. Analysis by Linker Type
15.3.2.7. Analysis by Key Geographical Regions
15.4. ADC Therapeutics: Demand and Supply Analysis
16. REGIONAL CAPABILITY ASSESSMENT ANALYSIS
16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Regional Capability Assessment in North America
16.4. Regional Capability Assessment in Europe
16.5. Regional Capability Assessment in Asia-Pacific Region
17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology
17.3. Overall ADC Therapeutics Market, 2020-2030
17.4. Input Data and Key Assumptions
17.5. Overall ADC Contract Manufacturing Market, 2020-2030
17.5.1. ADC Contract Manufacturing Market, 2020-2030: Distribution by Type of Component Manufacturing
17.5.2. ADC Contract Manufacturing Market, 2020-2030: Distribution by Phase of Development
17.6. ADC Contract Manufacturing Market for Commercial Products, 2020-2030
17.6.1. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Component Manufacturing
17.6.2. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Cancer
17.6.3. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Origin
17.6.4. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Antibody Isotype
17.6.5. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Payload Type
17.6.6. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Linker Type
17.6.7. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Key Geographical Regions
17.6.7.1. ADC Contract Manufacturing Market for Commercial Products in North America, 2020-2030
17.6.7.2. ADC Contract Manufacturing Market for Commercial Products in EU5, 2020-2030
17.6.7.2. ADC Contract Manufacturing Market for Commercial Products in Rest of the World, 2020-2030
17.7. ADC Contract Manufacturing Market for Clinical Products, 2020-2030
17.7.1. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Component Manufacturing
17.7.2. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Cancer
17.7.3. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Origin
17.7.4. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Antibody Isotype
17.7.5. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Payload Type
17.7.6. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Linker Type
17.7.7. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Key Geographical Regions
17.7.7.1. ADC Contract Manufacturing Market for Clinical Products in North America, 2020-2030
17.7.7.2. ADC Contract Manufacturing Market for Clinical Products in Europe, 2020-2030
17.7.7.3. ADC Contract Manufacturing Market for Clinical Products in Asia-Pacific, 2020-2030
17.7.7.4. ADC Contract Manufacturing Market for Clinical Products in MENA, 2020-2030
17.7.7.5. ADC Contract Manufacturing Market for Clinical Products in Latin America, 2020-2030
17.7.7.6. ADC Contract Manufacturing Market for Clinical Products in Rest of the World, 2020-2030
18. SWOT ANALYSIS
18.1. Chapter Overview
18.1.1. Strengths
18.1.2. Weaknesses
18.1.3. Opportunities
18.1.4. Threats
19. IMPACT OF COVID-19 PANDEMIC ON THE ADC CONTRACT MANUFACTURING MARKET
19.1 Chapter Overview
19.2. Current Opinions and Recuperative Initiatives of Key Players
19.2.1. ADC Biotechnology
19.2.2. Ajinomoto Bio-Pharma Services
19.2.3. CARBOGEN AMCIS
19.2.4. Goodwin Biotechnology
19.2.5. Lonza
19.2.6. Millipore Sigma
19.2.7. Novasep
19.2.8. Pierre Fabre
19.2.9. Piramal Pharma Solutions
19.2.10. Wuxi Biologics
19.3. Impact on ADC Contract Manufacturing Market
19.4. Recuperative Strategies for Contract Service Providers
19.4.1. Strategies for Implementation in the Short / Mid Term
19.4.2. Strategies for Implementation in the Long Term
20. CONCLUDING REMARKS
20.1. Chapter Overview
21. INTERVIEW TRANSCRIPTS
21.1. Chapter Overview
21.2. BSP Pharmaceuticals
21.2.1. Company Snapshot
21.2.2. Interview Transcript: Aldo Braca, Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager
21.3. Oxford BioTherapeutics
21.3.1. Company Snapshot
21.3.2. Interview Transcript: Christian Rohlff, Chief Executive Officer & Founder
21.4. Abzena
21.4.1. Company Snapshot
21.4.2. Interview Transcript: John Burt, Chief Executive Officer
21.5. Syndivia
21.5.1. Company Snapshot
21.5.2. Interview Transcript: Sasha Koniev, Chief Executive Officer & Co-Founder
21.6. Cerbios-Pharma
21.6.1. Company Snapshot
21.6.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
21.7. NBE-Therapeutics
21.7.1. Company Snapshot
21.7.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer
21.8. Eisai
21.8.1. Company Snapshot
21.8.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer
21.9. Synaffix
21.9.1. Company Snapshot
21.9.2. Interview Transcript: Anthony DeBoer, Director, Business Development
21.10. Pierre Fabre
21.10.1. Company Snapshot
21.10.2. Interview Transcript: Christian Bailly, Director of CDMO
21.11. Goodwin Biotechnology
21.11.1. Company Snapshot
21.11.2. Interview Transcript: David Cunningham, Director Corporate Development
21.12. Catalent Pharma Solutions
21.12.1. Company Snapshot
21.12.2. Interview Transcript: Jennifer L. Mitcham, Director, Business Development and Stacy McDonald, Group Product Manager
21.13. Lonza
21.13.1. Company Snapshot
21.13.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development
21.14. Piramal Pharma Solutions
21.14.1. Company Snapshot
21.14.2. Interview Transcript: Mark Wright, Site Head
21.15. Ajinomoto Bio-Pharma Services
21.15.1. Company Snapshot
21.15.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager
21.16. Anonymous, Director, Business Development, Leading CMO
21.17. Anonymous, Chief Executive Officer, Leading CMO
22. APPENDIX 1: TABULATED DATA
23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Key Components of an Antibody Drug Conjugate
Figure 3.2 ADC Manufacturing Steps
Figure 4.1 ADC Contract Manufacturing Service Providers: Distribution by Year of Establishment
Figure 4.2 ADC Contract Manufacturing Service Providers: Distribution by Company Size
Figure 4.3 ADC Contract Manufacturing Service Providers: Distribution by Service(s) Offered
Figure 4.4 ADC Contract Manufacturing Service Providers: Distribution by Other Service(s) Offered
Figure 4.5 ADC Contract Manufacturing Service Providers: Distribution by Scale of Operation
Figure 4.6 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Figure 4.7 ADC Contract Manufacturing Service Providers: Distribution by Service(s) Offered and Location of Headquarters
Figure 4.8 ADC Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Figure 6.1 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in North America
Figure 6.2 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in Europe
Figure 6.3 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in Asia-Pacific
Figure 7.1 Recent Expansions: Cumulative Year-wise Trend, 2012-2020
Figure 7.2 Recent Expansions: Distribution by Type of Facility Expansion
Figure 7.3 Recent Expansions: Distribution by Type of Service(s) Offered
Figure 7.4 Recent Expansions: Distribution by Year of Expansion and Type of Service(s) Offered
Figure 7.5 Recent Expansions: Distribution by Location of Expanded Facility
Figure 7.6 Recent Expansions: Distribution by Scale of Operation
Figure 7.7 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Figure 7.8 Most Active Players: Distribution by Number of Expansions
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2020
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Most Active Players: Distribution by Number of Partnerships
Figure 8.4 Partnerships and Collaborations: Regional Distribution
Figure 8.5 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.1 Make versus Buy Decision Making Framework
Figure 10.1 Value Chain Analysis: ADC Development Overview
Figure 10.2 ADC Contract Manufacturing Value Chain Overview
Figure 10.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing (%)
Figure 10.4 Value Chain Analysis: Distribution by Cost
Figure 10.5 Costs Associated with Antibody Manufacturing
Figure 10.6 Costs Associated with Payload and Linker Manufacturing
Figure 10.7 Costs Associated with Conjugation
Figure 10.8 Costs Associated with Fill / Finish
Figure 11.1 Capacity Analysis: Distribution by Company Size
Figure 11.2 Capacity Analysis: Distribution by Location of Headquarters
Figure 11.3 Capacity Analysis: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 11.4 Capacity Analysis: Distribution by Location of Manufacturing Facilities (Continent-wise)
Figure 11.5 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Figure 12.1 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Phase of Development
Figure 12.2 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Target Indication
Figure 12.3 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Solid Tumor
Figure 12.4 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Hematological Malignancies
Figure 12.5 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Target Antigen
Figure 12.6 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Antibody Origin
Figure 12.7 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Antibody Isotype
Figure 12.8 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Payload / Warhead
Figure 12.9 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Linker
Figure 12.10 ADC Therapeutics (Preclinical Pipeline): Distribution by Key Technology Providers
Figure 13.1 ADC Conjugation Platforms: Technological Evolution
Figure 13.2 ADC Conjugation Platforms: Technology Landscape
Figure 14.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 14.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 14.4 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 14.5 Clinical Trial Analysis: Distribution by Type of Cancer
Figure 14.6 Most Active Industry Players: Distribution by Number of Registered Studies
Figure 14.7 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Figure 14.8 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 14.9 Geographical Clinical Trial Analysis: Distribution by Antibody Isotype
Figure 14.10 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Phase
Figure 14.11 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Status
Figure 14.12 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Enrolled Patient Population
Figure 14.13 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Trial Phase
Figure 14.14 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Trial Status
Figure 14.15 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Enrolled Patient Population
Figure 14.16 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Phase
Figure 14.17 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Status
Figure 14.18 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Enrolled Patient Population
Figure 14.19 Geographical Clinical Trial Analysis: Distribution by Payload Type
Figure 14.20 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase
Figure 14.21 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Status
Figure 14.22 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Figure 14.23 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase
Figure 14.24 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Status
Figure 14.25 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Figure 14.26 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase
Figure 14.27 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Status
Figure 14.28 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Figure 14.29 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Trial Phase
Figure 14.30 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Trial Status
Figure 14.31 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Enrolled Patient Population
Figure 14.32 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Phase
Figure 14.33 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Status
Figure 14.34 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Enrolled Patient Population
Figure 14.35 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Trial Phase
Figure 14.36 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Trial Status
Figure 14.37 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Enrolled Patient Population
Figure 14.38 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Phase
Figure 14.39 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Status
Figure 14.40 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Enrolled Patient Population
Figure 14.41 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Figure 14.42 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase
Figure 14.43 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Status
Figure 14.44 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Figure 14.45 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase
Figure 14.46 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Status
Figure 14.47 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Figure 14.48 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase
Figure 14.49 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Status
Figure 14.50 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Figure 14.51 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Phase
Figure 14.52 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Status
Figure 14.53 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Enrolled Patient Population
Figure 14.54 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase
Figure 14.55 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Status
Figure 14.56 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Figure 14.57 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Trial Phase
Figure 14.58 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Trial Status
Figure 14.59 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Enrolled Patient Population
Figure 14.60 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Phase
Figure 14.61 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Status
Figure 14.62 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Enrolled Patient Population
Figure 15.1 Global Demand for ADC Therapeutics (in kgs), 2020-2030
Figure 15.2 Global Demand for ADC Therapeutics: Distribution by Scale of Operation, 2020-2030 (in kgs)
Figure 15.3 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Cancer, 2020-2030 (in kgs)
Figure 15.4 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2020-2030 (in kgs)
Figure 15.5 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Antibody Isotype, 2020-2030 (in kgs)
Figure 15.6 Global Commercial Demand for ADC Therapeutics: Distribution by Payload Type, 2020-2030 (in kgs)
Figure 15.7 Global Commercial Demand for ADC Therapeutics: Distribution by Linker Type, 2020-2030 (in kgs)
Figure 15.8 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2020-2030 (in kgs)
Figure 15.9 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Cancer, 2020-2030 (in kgs)
Figure 15.10 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2020-2030 (in kgs)
Figure 15.11 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2020-2030 (in kgs)
Figure 15.12 Global Clinical Demand for ADC Therapeutics: Distribution by Payload Type, 2020-2030 (in kgs)
Figure 15.13 Global Clinical Demand for ADC Therapeutics: Distribution by Linker Type, 2020-2030 (in kgs)
Figure 15.14 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2020-2030 (in kgs)
Figure 15.15 ADC Therapeutics: Demand and Supply Scenario, 2020 - 2030
Figure 16.1 Regional Capability Assessment: North America
Figure 16.2 Regional Capability Assessment: Europe
Figure 16.3 Regional Capability Assessment: Asia-Pacific
Figure 17.1 Global ADC Therapeutics Market, 2020-2030 (USD Billion)
Figure 17.2 ADC Therapeutics Market: Relative Cost of Manufacturing by Type of Component Manufacturing
Figure 17.3 ADC Contract Manufacturing Market, 2020-2030: Distribution by Type of Component Manufacturing (USD Million)
Figure 17.4 ADC Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Million)
Figure 17.5 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Component Manufacturing (USD Million)
Figure 17.6 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Cancer (USD Million)
Figure 17.7 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Origin (USD Million)
Figure 17.8 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Isotype (USD Million)
Figure 17.9 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Payload Type (USD Million)
Figure 17.10 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Linker Type (USD Million)
Figure 17.11 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Key Geographical Regions (USD Million)
Figure 17.12 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of North America (USD Million)
Figure 17.13 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of EU5 (USD Million)
Figure 17.14 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of Rest of the World (USD Million)
Figure 17.15 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Component Manufacturing (USD Million)
Figure 17.16 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Cancer (USD Million)
Figure 17.17 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Origin (USD Million)
Figure 17.18 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Isotype (USD Million)
Figure 17.19 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Payload Type (USD Million)
Figure 17.20 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Linker Type (USD Million)
Figure 17.21 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Key Geographical Regions (USD Million)
Figure 17.22 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of North America (USD Million)
Figure 17.23 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Europe (USD Million)
Figure 17.24 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Asia-Pacific (USD Million)
Figure 17.25 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of MENA (USD Million)
Figure 17.26 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Latin America (USD Million)
Figure 18.1 SWOT Analysis: Harvey Ball Analysis
Figure 20.1 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030 (USD Billion)
Table 3.1 Common Cytotoxins Used for the Production of ADC Therapeutics
Table 3.2 Safebridge / OEL bands for HPAPI / Cytotoxic Payloads
Table 4.1 List of ADC Contract Manufacturing Service Providers
Table 4.2 ADC Contract Manufacturing Service Providers: Information on Service(s) Offered
Table 4.3 ADC Contract Manufacturing Service Providers: Information on Other Service(s) Offered
Table 4.4 ADC Contract Manufacturing Service Providers: Information on Scale of Operation and Available Capacity
Table 4.5 ADC Contract Manufacturing Service Providers: Information on Manufacturing Facilities
Table 4.6 ADC Contract Manufacturing Service Providers: List of Antibody Manufacturing Service Providers
Table 4.7 ADC Contract Manufacturing Service Providers: List of HPAPI and Cytotoxic Drug Manufacturing Service Providers
Table 5.1 AbbVie Contract Manufacturing: Company Overview and Financial Information
Table 5.2 AbbVie Contract Manufacturing: ADC Related Offerings
Table 5.3 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
Table 5.4 AbbVie Contract Manufacturing: Recent Developments
Table 5.5 AbbVie Contract Manufacturing: Future Outlook
Table 5.6 ADC Biotechnology: Company Overview and Financial Information
Table 5.7 ADC Biotechnology: ADC Related Offerings
Table 5.8 ADC Biotechnology: Information on Manufacturing Facilities
Table 5.9 ADC Biotechnology: Recent Developments
Table 5.10 ADC Biotechnology: Future Outlook
Table 5.11 Ajinomoto Bio-Pharma Services: Company Overview
Table 5.12 Ajinomoto Bio-Pharma Services: ADC Related Offerings
Table 5.13 Ajinomoto Bio-Pharma Services: Information on Manufacturing Facilities
Table 5.14 Ajinomoto Bio-Pharma Services: Recent Developments
Table 5.15 Ajinomoto Bio-Pharma Services: Future Outlook
Table 5.16 BOC SCIENCES: Company Overview and Financial Information
Table 5.17 BOC SCIENCES: ADC Related Offerings
Table 5.18 BOC SCIENCES: Information on Manufacturing Facilities
Table 5.19 BOC SCIENCES: Recent Developments
Table 5.20 BSP Pharmaceuticals: Company Overview
Table 5.21 BSP Pharmaceuticals: ADC Related Offerings
Table 5.22 BSP Pharmaceuticals: Information on Manufacturing Facilities
Table 5.23 BSP Pharmaceuticals: Recent Developments
Table 5.24 BSP Pharmaceuticals: Future Outlook
Table 5.25 CARBOGEN AMCIS: Company Overview
Table 5.26 CARBOGEN AMCIS: ADC Related Offerings
Table 5.27 CARBOGEN AMCIS: Information on Manufacturing Facilities
Table 5.28 CARBOGEN AMCIS: Recent Developments
Table 5.29 CARBOGEN AMCIS: Future Outlook
Table 5.30 Cerbios-Pharma: Company Overview
Table 5.31 Cerbios-Pharma: ADC Related Offerings
Table 5.32 Cerbios-Pharma: Information on Manufacturing Facilities
Table 5.33 Cerbios-Pharma: Recent Developments
Table 5.34 Cerbios-Pharma: Future Outlook
Table 5.35 Creative Biolabs: Company Overview
Table 5.36 Creative Biolabs: ADC Related Offerings
Table 5.37 Creative Biolabs: Information on Manufacturing Facilities
Table 5.38 Creative Biolabs: Recent Developments
Table 5.39 Creative Biolabs: Future Outlook
Table 5.40 Goodwin Biotechnology: Company Overview
Table 5.41 Goodwin Biotechnology: ADC Related Offerings
Table 5.42 Goodwin Biotechnology: Information on Manufacturing Facilities
Table 5.43 Goodwin Biotechnology: Recent Developments
Table 5.44 Goodwin Biotechnology: Future Outlook
Table 5.45 Lonza: Company Overview and Financial Information
Table 5.46 Lonza: ADC Related Offerings
Table 5.47 Lonza: Information on Manufacturing Facilities
Table 5.48 Lonza: Recent Developments
Table 5.49 Lonza: Future Outlook
Table 5.50 MabPlex: Company Overview
Table 5.51 MabPlex: ADC Related Offerings
Table 5.52 MabPlex: Information on Manufacturing Facilities
Table 5.53 MabPlex: Recent Developments
Table 5.54 MabPlex: Future Outlook
Table 5.55 Millipore Sigma: Company Overview
Table 5.56 Millipore Sigma: ADC Related Offerings
Table 5.57 Millipore Sigma: Information on Manufacturing Facilities
Table 5.58 Millipore Sigma: Recent Developments
Table 5.59 Millipore Sigma: Future Outlook
Table 5.60 Novasep: Company Overview
Table 5.61 Novasep: ADC Related Offerings
Table 5.62 Novasep: Information on Manufacturing Facilities
Table 5.63 Novasep: Recent Developments
Table 5.64 Novasep: Future Outlook
Table 5.65 Pierre Fabre: Company Overview and Financial Information
Table 5.66 Pierre Fabre: ADC Related Offerings
Table 5.67 Pierre Fabre: Information on Manufacturing Facilities
Table 5.68 Pierre Fabre: Recent Developments
Table 5.69 Pierre Fabre: Future Outlook
Table 5.70 Piramal Pharma Solutions: Company Overview and Financial Information
Table 5.71 Piramal Pharma Solutions: ADC Related Offerings
Table 5.72 Piramal Pharma Solutions: Information on Manufacturing Facilities
Table 5.73 Piramal Pharma Solutions: Recent Developments
Table 5.74 Piramal Pharma Solutions: Future Outlook
Table 5.75 WuXi Biologics: Company Overview and Financial Information
Table 5.76 WuXi Biologics: ADC Related Offerings
Table 5.77 WuXi Biologics: Information on Manufacturing Facilities
Table 5.78 WuXi Biologics: Recent Developments
Table 5.79 WuXi Biologics: Future Outlook
Table 7.1 ADC Contract Manufacturing Service Providers: Recent Facility Expansions, 2012-2020
Table 8.1 ADC Contract Manufacturing Service Providers: Partnerships and Collaborations, 2012-2020
Table 11.1 Installed Global Capacity for ADC Manufacturing: Sample Data Set
Table 11.2 Installed Global Capacity for ADC Manufacturing: Sample Data Set (Average Capacity)
Table 11.3 Installed Global Capacity for ADC Manufacturing: Total Capacity Analysis, based on Company Size
Table 12.1 ADC Therapeutics: Approved / Clinical Stage Candidatesd
Table 12.2 ADC Therapeutics: Clinical Pipeline (Information on Linkers and Payloads)
Table 12.3 ADC Therapeutics: Preclinical / Discovery Pipeline
Table 13.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 13.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 13.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 13.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 13.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 13.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 13.7 Third Generation ADC Technologies: Cysteine Rebridging
Table 13.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 14.1 Geographical Clinical Trial Analysis (IgG1 based Molecules): Duration of Trials
Table 14.2 Geographical Clinical Trial Analysis (IgG2 based Molecules): Duration of Trials
Table 14.3 Geographical Clinical Trial Analysis (IgG4 based Molecules): Duration of Trials
Table 14.4 Geographical Clinical Trial Analysis (Auristatin based Molecules): Duration of Trials
Table 14.5 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Duration of Trials
Table 14.6 Geographical Clinical Trial Analysis (Calicheamicin Based Molecules): Duration of Trials
Table 14.7 Geographical Clinical Trial Analysis (PBD based Molecules): Duration of Trials
Table 14.8 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Duration of Trials
Table 14.9 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline Based Molecules): Duration of Trials
Table 14.10 Geographical Clinical Trial Analysis (Other Payload based Molecules): Duration of Trials
Table 14.11 Geographical Clinical Trial Analysis (VC based Molecules): Duration of Trials
Table 14.12 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Duration of Trials
Table 14.13 Geographical Clinical Trial Analysis (SMCC based Molecules): Duration of Trials
Table 14.14 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Duration of Trials
Table 14.15 Geographical Clinical Trial Analysis (SPDB based Molecules): Duration of Trials
Table 14.16 Geographical Clinical Trial Analysis (MC based Molecules): Duration of Trials
Table 14.17 Geographical Clinical Trial Analysis (Other Linker based Molecules): Duration of Trials
Table 17.1 ADC Therapeutics: Development Status of Late Stage Candidates
Table 17.2 ADC Therapeutics: Outsourcing Activity for Late Stage Candidates
Table 23.1 ADC Contract Manufacturing Service Providers: Distribution by Year of Establishment
Table 23.2 ADC Contract Manufacturing Service Providers: Distribution by Company Size
Table 23.3 ADC Contract Manufacturing Service Providers: Distribution by Service(s) Offered
Table 23.4 ADC Contract Manufacturing Service Providers: Distribution by Other Service(s) Offered
Table 23.5 ADC Contract Manufacturing Service Providers: Distribution by Scale of Operation
Table 23.6 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Table 23.7 ADC Contract Manufacturing Service Providers: Distribution by Service(s) Offered and Location of Headquarters
Table 23.8 Recent Expansions: Cumulative Year-wise Trend, 2012-2020
Table 23.9 Recent Expansions: Distribution by Type of Facility Expansion
Table 23.10 Recent Expansions: Distribution by Type of Service(s) Offered
Table 23.11 Recent Expansions: Distribution by Year of Expansion and Type of Service(s) Offered
Table 23.12 Recent Expansions: Distribution by Location of Expanded Facility
Table 23.13 Recent Expansions: Distribution by Scale of Operation
Table 23.14 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Table 23.15 Most Active Players: Distribution by Number of Expansions
Table 23.16 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2020
Table 23.17 Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.18 Most Active Players: Distribution by Number of Partnerships
Table 23.19 Partnerships and Collaborations: Regional Distribution
Table 23.20 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 23.21 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing (%)
Table 23.22 Value Chain Analysis: Distribution by Cost
Table 23.23 Capacity Analysis: Distribution by Company Size
Table 23.24 Capacity Analysis: Distribution by Location of Headquarters
Table 23.25 Capacity Analysis: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 23.26 Capacity Analysis: Distribution by Location of Manufacturing Facilities (Continent-wise)
Table 23.27 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Phase of Development
Table 23.28 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Target Indication
Table 23.29 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Solid Tumor
Table 23.30 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Hematological Malignancies
Table 23.31 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Target Antigen
Table 23.32 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Antibody Origin
Table 23.33 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Antibody Isotype
Table 23.34 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Payload / Warhead
Table 23.35 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Linker
Table 23.36 ADC Therapeutics (Preclinical Pipeline): Distribution by Key Technology Providers
Table 23.37 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 23.38 Clinical Trial Analysis: Distribution by Trial Phase
Table 23.39 Clinical Trial Analysis: Distribution by Trial Status
Table 23.40 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 23.41 Clinical Trial Analysis: Distribution by Type of Cancer
Table 23.42 Most Active Industry Players: Distribution by Number of Registered Studies
Table 23.43 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Table 23.44 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Table 23.45 Geographical Clinical Trial Analysis: Distribution by Antibody Isotype
Table 23.46 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Phase
Table 23.47 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Status
Table 23.48 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Enrolled Patient Population
Table 23.49 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Trial Phase
Table 23.50 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Trial Status
Table 23.51 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Enrolled Patient Population
Table 23.52 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Phase
Table 23.53 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Status
Table 23.54 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Enrolled Patient Population
Table 23.55 Geographical Clinical Trial Analysis: Distribution by Payload Type
Table 23.56 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase
Table 23.57 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Status
Table 23.58 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Table 23.59 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase
Table 23.60 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Status
Table 23.61 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Table 23.62 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase
Table 23.63 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Status
Table 23.64 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Table 23.65 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Trial Phase
Table 23.66 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Trial Status
Table 23.67 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Enrolled Patient Population
Table 23.68 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Phase
Table 23.69 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Status
Table 23.70 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Enrolled Patient Population
Table 23.71 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Trial Phase
Table 23.72 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Trial Status
Table 23.73 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Enrolled Patient Population
Table 23.74 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Phase
Table 23.75 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Status
Table 23.76 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Enrolled Patient Population
Table 23.77 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Table 23.78 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase
Table 23.79 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Status
Table 23.80 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Table 23.81 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase
Table 23.82 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Status
Table 23.83 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Table 23.84 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase
Table 23.85 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Status
Table 23.86 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Table 23.87 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Phase
Table 23.88 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Status
Table 23.89 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Enrolled Patient Population
Table 23.90 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase
Table 23.91 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Status
Table 23.92 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Table 23.93 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Trial Phase
Table 23.94 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Trial Status
Table 23.95 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Enrolled Patient Population
Table 23.96 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Phase
Table 23.97 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Status
Table 23.98 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Enrolled Patient Population
Table 23.99 Global Demand for ADC Therapeutics (in kgs), 2020-2030
Table 23.100 Global Demand for ADC Therapeutics: Distribution by Scale of Operation, 2020-2030 (in kgs)
Table 23.101 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Cancer, 2020-2030 (in kgs)
Table 23.102 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2020-2030 (in kgs)
Table 23.103 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Antibody Isotype, 2020-2030 (in kgs)
Table 23.104 Global Commercial Demand for ADC Therapeutics: Distribution by Payload Type, 2020-2030 (in kgs)
Table 23.105 Global Commercial Demand for ADC Therapeutics: Distribution by Linker Type, 2020-2030 (in kgs)
Table 23.106 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2020-2030 (in kgs)
Table 23.107 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Cancer, 2020-2030 (in kgs)
Table 23.108 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2020-2030 (in kgs)
Table 23.109 Global Clinical Demand for ADC Therapeutics: Distribution by Payload Type, 2020-2030 (in kgs)
Table 23.110 Global Clinical Demand for ADC Therapeutics: Distribution by Linker Type, 2020-2030 (in kgs)
Table 23.111 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2020-2030 (in kgs)
Table 23.112 ADC Therapeutics: Demand and Supply Scenario, 2020 - 2030
Table 23.113 Regional Capability Assessment: North America
Table 23.114 Regional Capability Assessment: Europe
Table 23.115 Regional Capability Assessment: Asia-Pacific
Table 23.116 Global ADC Therapeutics Market, 2020-2030 (USD Billion)
Table 23.117 ADC Therapeutics Market: Relative Cost of Manufacturing by Type of Component Manufacturing
Table 23.118 ADC Contract Manufacturing Market, 2020-2030: Distribution by Type of Component Manufacturing, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.119 ADC Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.120 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Component Manufacturing, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.121 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Cancer, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.122 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Origin, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.123 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Isotype, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.124 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Payload Type, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.125 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Linker Type, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.126 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.127 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of North America, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.128 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of EU5, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.129 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of Rest of the World, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.130 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Component Manufacturing, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.131 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Cancer, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.132 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Origin, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.133 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Isotype, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.134 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Payload Type, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.135 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Linker Type, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.136 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.137 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of North America, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.138 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Europe, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.139 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Asia-Pacific, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.140 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of MENA, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.141 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Latin America, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.142 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030 (USD Billion)
The following companies and organizations have been mentioned in the report.
Discounts available for multiple report purchases
sales@rootsanalysis.com